Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H2-TAT peptides are synthetic chimeric cell-penetrating peptides that combine the HIV trans-activator of transcription (TAT) protein transduction domain with a pH-responsive hemagglutinin 2 (HA2) domain from influenza A virus. The TAT domain is rich in arginine and lysine residues and facilitates efficient cellular entry by interacting with cell membranes through electrostatic interactions. The HA2 segment enables endosomal escape via pH-dependent membrane fusion activity. Together, these domains synergistically enhance intracellular delivery of various cargoes such as siRNA or drugs by promoting both cellular uptake and endosomal release. H2-TAT peptides have been studied primarily as nonviral vectors for gene silencing applications and drug delivery systems in cancer research. They protect nucleic acids from degradation and improve cytoplasmic delivery efficiency without significant toxicity[1]. Their performance depends on the mode of attachment to cargoes (e.g., multicomponent complexes or conjugates), which affects their surface configuration and biological activity[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on H2-TAT peptides.